Results from two clinical trials on ianalumab for Sjögren disease show favorable safety and adverse event outcomes, contributing to this designation.
Medscape Medical News
Source link : https://www.medscape.com/viewarticle/fda-makes-ianalumab-breakthrough-therapy-sj%C3%B6gren-2026a10001ob?src=rss
Author :
Publish date : 2026-01-19 10:26:00
Copyright for syndicated content belongs to the linked Source.